Tumor biomarkers have been considered as indicators of tumor extent for over 30 years. They have been used mainly for monitoring cancer patients after resection of the primary tumor or during the treatment of metastatic disease. In the last decade, several molecular mechanisms responsible for cancer development and dissemination have been highlighted (1) . The knowledge of biological mechanisms related to diverse clinical behaviors is the basis for the development of molecular-targeted anticancer agents (2) . These advancements have led to the identification of new cancer biomarkers that are expected to play a role in the prediction of responsiveness to molecular-targeted anticancer agents and in monitoring the response to therapy (3, 4) . A number of methods are now commercially available for measuring biomarkers related to molecular mechanisms of cancer cell regulation, including adhesion molecules, markers of apoptosis, products of oncogenes and tumor suppressor genes, and angiogenic factors (4). However, conflicting results on the clinical role of biomarkers are still frequently reported, thus impairing their possible implementation in clinical practice.
As a matter of fact, biomarker assays, even the commercially available ones, are often far from an acceptable level of standardization. In addition, efforts to monitor and improve the quality of biomarker determination have been mainly focused on the analytical phase, while the pre-and postanalytical phases have received much less attention (5) . Unfortunately, the latter two account for a relevant percentage of errors in the diagnostic process. Several potential causes of weakness may indeed affect the reliability of information provided by biomarkers and explain -at least in part -the discrepancies observed in different clinical studies.
First of all, complex biological machineries are often oversimplified by determining -for practical reasonsonly a small number of biomarkers. For instance, the determination of ER in tumor tissue is used to assess the hormone responsiveness of breast cancer. However, the complexity of the estrogen-mediated cell regulation machinery cannot be accurately expressed solely by ER, since i) two different ERs (ERα and ERβ) have been iden-tified (6); ii) several ER variants with impaired or modified functions have been found (7) ; iii) nuclear proteins (coactivators and corepressors) that modulate ER-induced transcription have been demonstrated (8); and iv) different ligand-independent activation mechanisms of ER have been described (9) . Not surprisingly, the prediction of the response to endocrine therapy is accurate in tumors that do not express ER, whereas it is unsatisfactory (50-60% accurate) in ER-positive cases. The availability of a panel of selective ER modulators (SERM), new agents suitable for cancer treatment and chemoprevention (10), further emphasizes the need for molecular targeting strategies based on a more comprehensive panel of biomarkers (7) . It is clear that an exhaustive investigation of the target biological machinery is the basis for the development and appropriate administration of new anticancer agents.
Secondly, variability of results may be related to the poor standardization of the analytical methods. For most of the cancer biomarkers no reference method has yet been established. Therefore, several biomarkers may be determined by using different approaches, i.e., gene expression, mRNA transcription, protein concentration or biological activity. This problem typically affects the results of HER-2/neu determination when immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are compared (11) .
Additional causes of potential variability (assay architecture, reagent type, etc.) may be present in every individual analytical approach. These potential causes of variability may lead to discrepancies that may not become apparent, since they occur in the same methodological category. For instance, the use of different antibodies may affect the comparability of results of immunohistochemistry. HER-2/neu is again a paradigmatic example; among 28 commonly used antibodies, 18 correctly detect the oncogene when it is amplified fivefold or more; however, only 12 of these 18 can identify the antigen when it is amplified two-to fivefold (12) .
Unexpected biases may occur even when the same method and the same reagents are used, because the molecular structure of the antigen may change according to its functional status. For instance, a commercially available enzyme-immunoassay may measure significantly different ER levels in the same tissue sample when buffers with different ionic strength are used for cytosol preparation (13) . This is due to the different reactivity of one of the monoclonal antibodies of the kit for the different functional statuses of ER (13) .
The preanalytical phase should also be considered as a potential cause of variability. In general, sample collection, handling, storage and preparation are not standardized. Several factors may significantly affect antigen detection in immunohistochemistry, including the fixative used, time of fixation, inclusion method, time of paraffin embedding, thickness of the sections, storage of unstained slides, and methods for antigen retrieval. Problems with standardization of the preanalytical phase are not limited to the determination of biomarkers in the tissue. The assay for circulating vascular endothelial growth factor (VEGF) provides a clear example of the potential biases related to the lack of standardization of blood collection. Different studies reported variable VEGF levels in serum, plasma and whole blood hemolysate. In addition, VEGF levels change significantly according to the procedure used to prepare serum or plasma. Clotting time increases the release of VEGF, which reaches a plateau between two and four hours. The percent increase in VEGF at two hours ranges from 118% to 4515% with respect to the levels found in samples centrifuged within 10 minutes from withdrawal (14) . However, in spite of these problems, several investigators have published promising results on serum VEGF as a cancer biomarker, providing scarce, if any, information on the standardization of the preanalytical phase. The standardization of sample preparation has not been considered in a recent review article in which the potential clinical role of VEGF is extensively discussed (15) .
Thirdly, for practical reasons biomarker levels are usually expressed as positive or negative with respect to a cutoff point. However, cutoff points present pitfalls and drawbacks (16) , for the relationship between a biomarker and clinical outcome is not necessarily dichotomous and may be either continuous monotonous or non-monotonous (17) . Dichotomous decision criteria may affect the value of a biomarker when continuous monotonous relationships occur, because cases with a variable degree of association with prognosis are arbitrarily combined. The occurrence of non-monotonous relationships may cause even more meaningful biases when using a positive/negative cutoff, since patients with opposite prognoses are included in the same category.
Continuous monotonous relationships between biomarkers and prognosis have been shown for p53, for the cytokeratin-associated marker tissue polypeptide antigen and for ER in breast cancer cytosols (17, 18) . Non-monotonous continuous relationships have been reported for VEGF and for HER2/neu in node-negative breast can-cer patients (17, 18) . In addition, different biomarkers can elicit complex interactions that may significantly affect their clinical significance. Complex interactions between biomarkers and clinical outcome have been reported by several investigators (17, 18) . Dichotomous criteria may in some cases be used for practical reasons. However, a preliminary evaluation of the biomarker should be performed on its original measurement scale. This allows thorough exploration of the relationships between the biomarker and clinical outcome and improves the knowledge of the underlying biological mechanisms.
In conclusion, biomarkers are expected soon to play a key role in the emerging individually-tailored therapeutic approaches to cancer. Therefore, strict standardization of the analytical process and rigorous quality assurance programs are necessary to limit laboratory biases that could affect their reliable clinical use. When scrutinizing published studies on the clinical evaluation of biomarkers, one rarely finds international criteria of analytical validation (i.e., NCCLLS) either put into practice or just mentioned (19) . The uncritical use of laboratory data obtained with non-standardized approaches bears the risk of increasing the confusion regarding the actual biological role and clinical usefulness of new biomarkers.
Editors of various journals have endorsed a number of initiatives aimed at standardizing the methodology for planning, performing and reporting clinical trials and the criteria for peer-reviewing clinical studies (20, 21) . However, efforts to standardize the use of biomarkers in clinical studies have only been anecdotally considered (22, 23) . The use of non-standardized laboratory approaches may bias the potential clinical usefulness of new biomarkers, ultimately impairing the evaluation and prompt clinical availability of new anticancer agents. Working criteria for the standardization of biomarker use in investigational trials and clinical practice are urgently needed and have recently been proposed (24, 25) .
